AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03535896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSR
Description: Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day.
Study NCT03535896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
Study NCT00934050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005 (scyllo-inositol)
Description: Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Study NCT01294787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol and glycopyrronium bromide (QVA149)
Study NCT01294787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01294787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study NCT03339141 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intubation position
Description: The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
Study NCT02209285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Program for Older Adults with Multimorbidity
Description: Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
Study NCT01521533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: Pilot Group (NOX A12 single agent, and combined with VD):~* 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.
Study NCT03267381 — intervention group
Intervention type: OTHER
Intervention: Blood draw (before surgery)
Description: Blood will be drawn before surgery
Study NCT03267381 — intervention group
Intervention type: OTHER
Intervention: Blood draw (every 3 months)
Description: Blood will be drawn every 3 months
Study NCT03267381 — intervention group
Intervention type: OTHER
Intervention: Blood draw (at diagnosis)
Description: Blood will be drawn at time of diagnosis
Study NCT03045250 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Corneal confocal microscopy
Description: Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
Study NCT03045250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal confocal microscopy
Description: Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
Study NCT03045250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
Study NCT03045250 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nerve conduction study
Description: Nerve conduction studies will be use to assess for neuropathy.
Study NCT03045250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve conduction study
Description: Nerve conduction studies will be use to assess for neuropathy.
Study NCT03045250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Subjects will undergo a one time blood draw for biomarkers.
Study NCT03045250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Subjects will undergo a one time blood draw for biomarkers.
Study NCT00426647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study NCT00426647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Study NCT01741948 — intervention group
Intervention type: DRUG
Intervention: Hormonal contraceptive
Description: The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy.
Study NCT02281877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: 5x/week, 2x/day, for 45 minutes/session
Study NCT04200612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Psychotherapy
Description: Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
Study NCT02281877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: Standard physical therapy after TKA
Study NCT04200612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Equine-Assisted Activities
Description: Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
Study NCT04200612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activities
Description: Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
Study NCT02281877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Protocol
Description: Standard physical therapy after TKA
Study NCT01191749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
Study NCT05219890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
Study NCT05219890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
Study NCT00183898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine
Description: cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
Study NCT01227811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Single oral dose Darisec(R) 15.0 mg
Study NCT01227811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: Single oral dose Enablex(R) 15 mg
Study NCT00694746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters
Description: Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
Study NCT00694746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
Study NCT02119000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG/electrolytes 2L/2L split dose
Description: Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
Study NCT02119000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose
Description: Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes
Study NCT01651585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir arrow
Description: dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
Study NCT02741817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
Study NCT02943759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem leaf extract
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial
Study NCT02943759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
Study NCT00408954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UK-369,003
Description: 100 mg MR tablet once daily for 2 weeks
Study NCT00408954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UK-369,003
Description: UK-369,003-100 mg MR formulation for 2 weeks
Study NCT04217356 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hematopoietic stem cell transplant
Description: Intravenous infusion of hematopoietic stem cells from a donor.
Study NCT04217356 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib
Description: Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
Study NCT04217356 — intervention group
Intervention type: DRUG
Intervention: Hydroxyurea
Description: Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
Study NCT03620279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magic camp intervention
Description: Hand-arm bimanual motor skills training
Study NCT01254877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: ondansetron 0.2 mg bid, oral preparation, 16 weeks
Study NCT01254877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ondansetron
Description: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
Study NCT01254877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
Study NCT02440867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Study NCT02440867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Study NCT02440867 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS
Description: Sham stimulation
Study NCT02529332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
Study NCT00303953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT01909271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Education Film Viewing
Description: A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
Study NCT01909271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stroke Education Pamphlet Exposure
Description: Usual Care: Stroke Education pamphlet and brochure distribution.
Study NCT03510000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
Study NCT03510000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single hormone artificial pancreas
Description: Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
Study NCT03510000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal strategies
Description: Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
Study NCT03695835 — intervention group
Intervention type: DRUG
Intervention: Immunotherapeutic Agents
Description: Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
Study NCT03695835 — intervention group
Intervention type: DEVICE
Intervention: Ablation
Description: Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
Study NCT03692962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Time in bed will be restricted to 5 hours per night for 7 nights.
Study NCT03692962 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep restriction
Description: Time in bed will be restricted to 5 hours per night for 7 nights.
Study NCT03692962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Description: Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
Study NCT03669471 — intervention group
Intervention type: OTHER
Intervention: Testing of performance
Description: The cross-sectional evaluation will involve assessment of:~1. Hip muscle function~2. Single leg jump performance~3. Self-reported hip and groin function~4. Evaluation of return to sport~5. Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk.
Study NCT03737019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education with Acceptance and Commitment Therapy
Description: Group education with Acceptance and Commitment Therapy of the personnel at each center.
Study NCT03737019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, no intervention
Description: Control, no interventions.
Study NCT04235075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG/PCG and ultrasound signal acquisition
Description: The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants.
Study NCT03509155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National portion & IYCF counseling
Description: Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
Study NCT03509155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjusted portion & local food counseling
Description: four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
Study NCT00287820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: olanzapine 5-40 mg/day
Study NCT00287820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 5-40 ,mg/day
Study NCT00287820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone 1-12 mg/day
Study NCT02617095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2762
Description: One drop in each eye 3 to 6 times daily
Study NCT02617095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: One drop in each eye 3 to 6 times daily
Study NCT04324840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: Specified dose on specified days
Study NCT04324840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Specified dose on specified days
Study NCT04324840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified days
Study NCT04324840 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Specified dose on specified days
Study NCT04032223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placemet in the mandibular canine regions
Description: Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
Study NCT04032223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placemet in the mandibular canine regions
Description: Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
Study NCT01910441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg twice daily